Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RETREG1 antisense RNA 1 is a long non-coding RNA (lncRNA) transcribed opposite to the RETREG1 (FAM134B) gene locus. The primary presumed function of RETREG1-AS1 is regulation of its sense counterpart RETREG1, a key protein involved in reticulophagy—selective autophagy of the endoplasmic reticulum—and neuronal survival[7]. Like other antisense RNAs, RETREG1-AS1 likely modulates gene expression post-transcriptionally, possibly by hybridizing to RETREG1 mRNA to affect its stability, translation, or splicing, or by recruiting epigenetic modifiers[2][7][12]. There is no current evidence of direct drug targeting, clinical biomarker relevance, or safety issues for RETREG1-AS1, and its specific molecular and disease roles remain to be clarified. Its expression and functional regulation may be important in conditions linked to RETREG1, such as hereditary neuropathies[1][4][7], but it is not considered a classical drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RETREG1 antisense RNA 1 (RETREG1-AS1).